Docket #: S20-354
Hypersensitivity Associated with IL-1 and IL-6 Inhibitors Links to Common HLA Alleles
Researchers at Stanford and UCSF have discovered a strong association between serious, potentially fatal, delayed hypersensitivity reactions that occur in a subset of patients exposed to IL-1/IL-6 inhibitors and HLA-DRB1*15 alleles that are common across ancestries. Anti-IL-1/6 therapies are commonly used to treat inflammatory conditions and this finding suggests that HLA testing before prescription, treatment monitoring, and applicable drug safety labeling could improve safety. Misinterpreted as disease flares, Drug reaction with eosinophilia and systemic symptoms (DRESS), a severe delayed hypersensitivity reaction (DHR), often goes unrecognized in patients with inflammatory illness. Unusual clinical features including severe drug-associated lung disease and rash arising during IL-1 and IL-6 inhibitor treatment of Still's and Still's-like disease across the age spectrum [systemic onset juvenile arthritis (sJIA) and adult onset Stills disease (AOSD)] suggested this serious DHR to the researchers. See publication of Saper and Mellins et al. for more information on their multi-center, retrospective study of a convenience sample of IL-1 or IL-6 inhibitor-exposed cases of Still's and Kawasaki disease.
Stage of Development
Ready for clinical use
Applications
- Identification of at-risk patients
- Safe and effective administration of therapeutics
Advantages
- Screening for risk-associated HLA alleles may help avoid serious adverse reactions, and focus drugs where they will provide the best outcome
Publications
- Saper VE, Ombrello MJ, Tremoulet AH, et al. Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles Annals of the Rheumatic Diseases. Published Online First: 17 November 2021.
Related Links
Patents
- Published Application: WO2022174067
- Published Application: 20240093299
Similar Technologies
-
Mouse Model for Phosphodiesterase (PDE4D) Deficiency S98-097Mouse Model for Phosphodiesterase (PDE4D) Deficiency
-
Drug-imprinted hydrogel for controlled-release wound healing therapy with FAK inhibitors S14-447Drug-imprinted hydrogel for controlled-release wound healing therapy with FAK inhibitors
-
Targeting Osteopontin: Novel Strategy to Treat Cancer and Inflammation S19-253Targeting Osteopontin: Novel Strategy to Treat Cancer and Inflammation